Active Pharmaceutical Ingredients Market Size to Reach USD 512.13 Billion at 7.98% CAGR by 2030 | MRFR

Market Research Future (MRFR) has published a cooked research report on the “Global Active Pharmaceutical Ingredients Market” that contains information from 2018 to 2030. The Active Pharmaceutical Ingredients market is estimated to register a CAGR of 7.98% during the forecast period of 2023 to 2030.

Market Highlights

The global Active Pharmaceutical Ingredients market is accounted to register a CAGR of 7.98% during the forecast period and is estimated to reach USD 512.13 billion by 2030.

The Active Pharmaceutical Ingredients (API) Market refers to the global industry involved in the production and supply of the chemical compounds that are used as the primary active components in pharmaceutical drugs. These ingredients are responsible for the therapeutic effects of medications and are manufactured by pharmaceutical companies or contracted third-party manufacturers.

Segment Analysis

The global Active Pharmaceutical Ingredients market has been segmented based on Manufacturing Process, Type, API Formulation, Application and Molecules.

On the basis of Manufacturing Process, the market is segmented into captive manufacturing and contract manufacturing. The market revenue for active pharmaceutical ingredients was dominated in 2021 by the captive production sector. It is anticipated to expand rapidly over the coming years as a result of the easy availability of raw materials and major investments made by key players to construct high-end manufacturing facilities.

Based on Type, the global Active Pharmaceutical Ingredients market has been segmented into synthetic and biotech. In 2021, the synthetic sector dominated the market, and it is anticipated that over the forecast period, 2022–2030, it will increase more quickly than any other section.

Based on API Formulation, the global Active Pharmaceutical Ingredients market has been segmented into generic API and branded/innovative API. The innovative API segment dominated the market in 2021 and is anticipated to grow at the fastest rate from 2022 to 2030. This growth is attributed to increased R&D efforts for developing novel medications and beneficial governmental regulations.

Based on Application, the global Active Pharmaceutical Ingredients market has been segmented into cardiovascular disease, oncology, neurological disorders, orthopedic disorders, respiratory, gastrointestinal disorders, urology, and others. In 2021, cardiovascular illnesses accounted for the biggest segment share. The increased prevalence of the target disorders explains it.

Based on Molecules, the global Active Pharmaceutical Ingredients market has been segmented into large and small molecules. In 2021, the small molecule had the highest segment share. Despite the introduction of novel biological entities to the market, small molecules are being used more and more in the therapeutic pipeline.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Active Pharmaceutical Ingredients Market Research Report

Key Players:

MRFR recognizes the following companies as the key players in the global Active Pharmaceutical Ingredients market— Sanofi SA (France), Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (US), Abbott (US), Bayer AG (UK), Merck & Co Inc (US), Boehringer Ingelheim GmbH (UK), GlaxoSmithKline Plc (UK), Novartis AG (UK), Eli Lilly and Company (US), and Teva Pharmaceutical Industries Ltd (Israel).

Regional Analysis

The global Active Pharmaceutical Ingredients market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Active Pharmaceutical Ingredients market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Active Pharmaceutical Ingredients market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Active Pharmaceutical Ingredients market comprises of Middle East, Africa, and Latin America.

The North America Active Pharmaceutical Ingredients Market dominated this market in 2022. It is anticipated to increase at a considerable CAGR throughout the study period, reaching USD 121.65 billion in 2021. Since the prevalence of chronic diseases and other neurological problems has increased due to advancements in diagnostic technology,

Additionally, the second-largest market share for Active Pharmaceutical Ingredients is held by Europe. The industry is anticipated to be driven by the increase in research funding and the local presence of important market players. The number of biopharmaceutical companies in Europe has expanded as a result of increased investments.

Moreover, Due to the prevalence of quickly rising markets like India, China, and South Korea, which are emerging as significant hubs for outsourcing drug manufacture, the Asia-Pacific Active Pharmaceutical Ingredients Market is anticipated to grow at the quickest CAGR from 2022 to 2030. In the Asia Pacific, Japan is expected to lead the market for active pharmaceutical ingredients. Additionally, the India active pharmaceutical ingredients market had the highest rate of growth in the Asia-Pacific region, while China's active pharmaceutical ingredients market had the largest market share.

Key Findings of the Study

• The North America Active Pharmaceutical Ingredients Market dominated this market in 2022. It is anticipated to increase at a considerable CAGR throughout the study period, reaching USD 121.65 billion in 2021.


• Based on Manufacturing Process, the market revenue for active pharmaceutical ingredients was dominated in 2021 by the captive production sector.


• Sanofi SA (France), Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (US), Abbott (US), Bayer AG (UK), Merck & Co Inc (US), Boehringer Ingelheim GmbH (UK), GlaxoSmithKline Plc (UK), Novartis AG (UK), Eli Lilly and Company (US), and Teva Pharmaceutical Industries Ltd (Israel).